Secarna Pharmaceuticals Unveils Promising SECN-15 Data at ASCO 2025

Secarna Pharmaceuticals will present new data on its leading antisense oligonucleotide program, SECN-15, at the upcoming ASCO Annual Meeting in Chicago. SECN-15 targets Neuropilin-1, presenting a novel therapeutic strategy for solid cancers where current immunotherapies are insufficient.

Initial results attest to SECN-15's significant anti-tumor activity and a favorable safety profile, successfully tested in mice and rats. Notably, SECN-15 demonstrates potential effectiveness as a single agent and in combination with immune checkpoint inhibitors.

The Phase I/II clinical trial will focus on gastric cancer, aiming to validate SECN-15’s efficacy and safety further. These developments underscore Secarna’s commitment to addressing cancers with high unmet medical needs.